Nigeria caps dulaglutide prescribing to 18 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
The Ledger
Page 4 of 25 of this archive, newest first.
Page 4
Italy caps exenatide prescribing to 19 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
Japan declines to reimburse liraglutide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
Chain of custody, and where it begins
Chain of custody, in a regulated setting, begins at sampling. Here it begins when the package arrives.
How a claim degrades between the bench and the listing
A badge asserts that something was tested. It does not assert what, when, on whose sample, by what method, or whether the lot on sale is the lot that was tested.
Ireland declines to reimburse liraglutide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
Side effects, cost, supply, target: four reasons with four trajectories
The trials studied planned withdrawal. Almost nobody stops that way.
An interlaboratory comparison nobody had run
The Journal submitted split samples from single lots to three assay services, under names unconnected to this publication, and published each method alongside each result.
South Korea caps liraglutide prescribing to 19 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
Denmark caps tirzepatide prescribing to 13 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
The shortage years, and what they taught about interruption
Why the reason for stopping changes what happens afterwards.
Singapore declines to reimburse tirzepatide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
South Korea declines to reimburse tirzepatide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
What SURMOUNT-3 tells us about maintenance, and what it does not
The commonest real-world strategy in this drug class is the least studied one.
The withdrawal trials, read as designs rather than warnings
Three randomised withdrawal designs have tested what happens when treatment stops. Their results are consistent and they are consistently misreported.
India caps exenatide prescribing to 17 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
Same material, different gradients, different answers
Two years ago we ran an anonymised version of this comparison and promised a named one. This is it, with every method printed in full.
Ireland declines to reimburse tirzepatide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
What a split-sample exercise can establish, and what it cannot
Duplicate submissions under different names test within-laboratory repeatability, which is a different quantity from between-laboratory reproducibility.
Argentina declines to reimburse dulaglutide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.